Etoposid Ebewe Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Etoposide

Indications/Uses

Recurrent or refractory testicular cancer, small-cell lung cancer, Hodgkin's & non-Hodgkin's lymphoma, acute myeloid leukaemia, gestational trophoblastic neoplasia, ovarian cancer.

Click to view Etoposid Ebewe detailed prescribing information

Dosage/Direction for Use

Adult 50-100 mg/m² daily by slow IV infusion over 30-60 min on days 1-5 or 100-120 mg/m² by slow IV infusion over 30-60 min on days 1, 3 & 5 every 3-4 wk in combination w/ other drugs indicated in the disease to be treated. Paed Hodgkin's & non-Hodgkin's lymphoma, acute myeloid leukaemia 75-150 mg/m² daily by slow IV infusion over 30-60 min for 2-5 days in combination w/ other antineoplastic agents. Renal impairment >50 mL/min 100% of dose, 15-50 mL/min 75% of dose.

Click to view Etoposid Ebewe detailed prescribing information

Overdosage

View Etoposid Ebewe overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity. Concomitant use of yellow fever or live vaccines in immunosuppressed patients. Lactation.

Click to view Etoposid Ebewe detailed prescribing information

Special Precautions

Reduce dose or discontinue treatment if severe reactions occur. Myelosuppression; secondary leukaemia; low serum albumin may be at increased risk of etoposide toxicities; tumour lysis syndrome. Measure haematological parameters (eg, platelet count, haemoglobin, WBC count & differential) at start of therapy & prior to each subsequent dose. May cause adverse reactions that affect ability to drive or use machines. Reduce dose in renal impairment. Monitor hepatic function regularly. Men & women should use effective contraception during treatment & up to 6 mth after treatment. Pregnancy. Paed <18 yr.

Click to view Etoposid Ebewe detailed prescribing information

Use In Pregnancy & Lactation

Click to view Etoposid Ebewe detailed prescribing information

Adverse Reactions

Anaemia, leucopenia, myelosuppression, neutropenia, thrombocytopenia; abdominal pain, anorexia, constipation, nausea & vomiting; hepatotoxicity, increased ALT, alkaline phosphatase, AST, bilirubin; alopecia, pigmentation; asthenia, malaise. Infection; acute leukaemia; anaphylactic reactions; dizziness; arrhythmia, MI; HTN, transient systolic hypotension following rapid IV administration; diarrhoea, mucositis (including stomatitis & oesophagitis); pruritus, rash, urticaria; extravasation, phlebitis.

Click to view Etoposid Ebewe detailed prescribing information

Drug Interactions

Increased exposure & decreased total body clearance w/ high dose ciclosporin. Reduced total body clearance w/ cisplatin. Increased clearance & reduced efficacy w/ phenytoin & other enzyme-inducing antiepileptic. Efficacy may be reduced w/ drugs known to inhibit phosphatase activity. May be displaced from plasma protein binding by phenylbutazone, Na salicylate & aspirin. Decreased seizure control w/ antiepileptic drugs. May elevate INR w/ warfarin. Increased risk of fatal systemic vaccinal disease w/ yellow fever vaccine, live vaccines (contraindicated). May have additive or synergetic effects w/ other drugs w/ similar myelosuppressant action. Cross resistance w/ anthracyclines.

Click to view Etoposid Ebewe detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Etoposid Ebewe detailed prescribing information

Storage

View Etoposid Ebewe storage conditions for details to ensure optimal shelf-life.

Description

View Etoposid Ebewe description for details of the chemical structure and excipients (inactive components).

Action

View Etoposid Ebewe mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01CB01 - etoposide ; Belongs to the class of plant alkaloids and other natural products, podophyllotoxin derivatives. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Etoposid Ebewe soln for infusion 20 mg/mL

Packing/Price

5 mL x 1's

Etoposid Ebewe

etoposide

Manufacturer:

EBEWE Pharma

Distributor:

Maxxcare

Marketer:

Mega Lifesciences